Search Page

1

Cite

A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT).

Domingos V, Nezvalova-Henriksen K, Dadkhah A, Moreno-Martinez ME, Ben Hassine K, Pires V, Kröger N, Bauters T, Hassan M, Duncan N, Kalwak K, Ansari M, Langebrake C, Admiraal R. Domingos V, et al. Among authors: dadkhah a. Bone Marrow Transplant. 2024 Dec;59(12):1641-1653. doi: 10.1038/s41409-024-02413-0. Epub 2024 Sep 13. Bone Marrow Transplant. 2024. PMID: 39271948 Review.

Cite

2

Cite

Clinically Relevant Drug Interactions in HCT.

Bauters T, Dadkhah A. Bauters T, et al. Among authors: dadkhah a. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 31. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 31. PMID: 39437077 Free Books & Documents. Review.

Cite

3

Cite

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.

Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard FE, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N. Rathje K, et al. Among authors: dadkhah a. Am J Hematol. 2025 Feb;100(2):200-209. doi: 10.1002/ajh.27529. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548811 Free PMC article.

Cite

4

Cite

A Unified Data Architecture for Assessing Motor Symptoms in Parkinson's Disease.

Gundler C, Zhu QR, Trübe L, Dadkhah A, Gutowski T, Rosch M, Langebrake C, Nürnberg S, Baehr M, Ückert F. Gundler C, et al. Among authors: dadkhah a. Stud Health Technol Inform. 2023 Sep 12;307:22-30. doi: 10.3233/SHTI230689. Stud Health Technol Inform. 2023. PMID: 37697834

Cite

5

Cite

Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives.

Wicha SG, Wansing EMA, Dadkhah A, Ayuk FA, Kröger NM, Langebrake C. Wicha SG, et al. Among authors: dadkhah a. Blood Adv. 2024 Feb 13;8(3):797-798. doi: 10.1182/bloodadvances.2023012068. Blood Adv. 2024. PMID: 38191740 Free PMC article. No abstract available.

Cite

6

Cite

Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital.

Rosch M, Gutowski T, Baehr M, Eggert J, Gottfried K, Gundler C, Nürnberg S, Langebrake C, Dadkhah A. Rosch M, et al. Among authors: dadkhah a. Int J Pharm. 2023 Aug 25;643:123218. doi: 10.1016/j.ijpharm.2023.123218. Epub 2023 Jul 17. Int J Pharm. 2023. PMID: 37467818 Free article.

Cite

7

Cite

Iron Chelation With Deferasirox Increases Busulfan AUC During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation.

Essmann S, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger NM, Langebrake C. Essmann S, et al. Among authors: dadkhah a. Transplant Cell Ther. 2022 Feb;28(2):115.e1-115.e5. doi: 10.1016/j.jtct.2021.11.003. Epub 2021 Nov 11. Transplant Cell Ther. 2022. PMID: 34775147 Free article.

Cite

8

Cite

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.

Dadkhah A, Wicha SG, Kröger N, Müller A, Pfaffendorf C, Riedner M, Badbaran A, Fehse B, Langebrake C. Dadkhah A, et al. Pharmaceutics. 2022 May 27;14(6):1145. doi: 10.3390/pharmaceutics14061145. Pharmaceutics. 2022. PMID: 35745718 Free PMC article.

Cite

9

Cite

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment.

Marquard F, Langebrake C, Janson D, Mahmud M, Dadkhah A, Kröger N, Ayuk F. Marquard F, et al. Among authors: dadkhah a. Front Oncol. 2023 Nov 14;13:1288764. doi: 10.3389/fonc.2023.1288764. eCollection 2023. Front Oncol. 2023. PMID: 38033500 Free PMC article.

Cite

10

Cite

Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.

Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, Kröger N. Klyuchnikov E, et al. Among authors: dadkhah a. Eur J Haematol. 2023 Feb;110(2):188-197. doi: 10.1111/ejh.13893. Epub 2022 Dec 1. Eur J Haematol. 2023. PMID: 36335432 Free article.

Cite